“A main priority for dermatologists, at this point, is to keep our patients out of emergency rooms and urgent care so as to not tax the health care system unnecessarily,” according to the guidance. “Dermatologists must delicately balance the risk of immunosuppression with the risk of disease flare requiring urgent intervention.”

With this in mind, it is strongly recommended by the AAD that patients should not cease biologic therapy without consulting the treating physician. Specifically, the Academy offers three bullet points for dermatologists to follow.